ANN ARBOR, Mich., April 21, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a world leader in spider silk technology*, is pleased to provide an update on recombinant spider silk production. The Company continues to increase its production output and is now in the middle of its largest-ever batch of recombinant spider silk production.

Kraig Labs can now report that it has successfully completed the first half of its current production batch and those spider silk cocoons are being prepared for reeling into finished silk. This second half of this production cycle is expected to be complete in the next 14 days. 

This current production run marks a significant milestone, as the first simultaneous batches of BAM-1 produced in the Company’s newest facilities. The initial results have been highly encouraging, demonstrating the robustness of the BAM-1 hybrids and the efficiency of the expanded production infrastructure. The concurrent operation of multiple batches has proceeded smoothly, underscoring the scalability and reliability of the Company’s production model.

In addition to the progress in silk production, Kraig Labs has completed the production of all BAM-1 hybrid eggs designated for release over the next month. This achievement ensures a steady supply of high-quality hybrids for upcoming production cycles, aligning with the Company’s strategic objectives and production goals for 2025.

“The successful execution of simultaneous production batches in our new facilities demonstrates the scalability of our technology from batch processing to continuous flow manufacturing,” said Kim Thompson, Founder and CEO of Kraig Labs. “With this cycle nearing completion and the next generation of BAM-1 hybrids already prepared, we are in a strong position to rapidly accelerate the growth and commercialization of our spider silk.”

Kraig Labs remains committed to advancing the commercialization of its eco-friendly and high-performance spider silk fibers. The Company will continue to provide updates as it progresses toward its production and commercialization goals.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Company Adopting Advanced Gene Editing Platform Across All Commercial Silkworm Development Programs

ANN ARBOR, MI – April 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology[1], today announced the successful rollout of a next-generation molecular biology and gene-splicing platform. This powerful new system represents a major leap forward in the Company’s ability to create and refine genetically engineered spider silk and other advanced materials. The Company has already validated the technology with a newly created transgenic.

Leveraging cutting-edge advancements in gene editing, this platform enables more precise, efficient, and versatile manipulation of DNA. As a result, Kraig Labs has rapidly developed a new transgenic silkworm, which is now undergoing evaluation testing and commercial application assessment.

This breakthrough empowers Kraig Labs to significantly accelerate its R&D pipeline for advanced materials and enhance material performance.

“Our adaption of this technology represents a transformative advancement for Kraig Labs and our entire molecular biology program,” said Company Founder and CEO, Kim Thompson. “With this platform in place, we are dramatically expanding the speed, scope, and sophistication of our genetic engineering capabilities. The successful creation of new transgenics using this system confirms its effectiveness. We are experimenting with two such platforms and will likely adopt one of them for all of our ongoing and future commercial silkworm development.”

Kraig Labs is now actively transitioning all of its silkworm biotechnology programs to these next-generation platforms, which is expected to drive increased efficiency, consistency, and performance in spider silk production.

This development marks another milestone in the Company’s mission to lead the commercialization of high-performance spider silk materials for a broad range of end markets, including technical textiles, defense, performance apparel, and medical textiles.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

[1]For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

ANN ARBOR, Mich., April 7, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk-based super materials, is pleased to announce the appointment of Dr. Xiaoli Zhang as Director of Molecular Biology.

Dr. Zhang is a proven research and development leader in the field of molecular biology and bioengineering, with numerous groundbreaking accomplishments in spider silk and transgenic silkworms, including publication and citations in peer-reviewed scientific journals. Her research has been pivotal in optimizing the Company’s genetic engineering of silkworms to produce high-performance spider silk.

In the very short time she has worked directly with Kraig Labs, she has rapidly achieved significant breakthroughs in the development of brand-new spider silk-based fibers that target capabilities beyond the currently available materials. The Company is now accelerating the transition of these new developments out of the laboratory with a focus on large-scale commercialization of these revolutionary materials.

“We are thrilled to recognize Dr. Zhang’s invaluable contributions to the development of advanced biomaterials, including spider silk, by appointing her to the pivotal position of Director of our Molecular Biology laboratory and R&D center,” said Kim Thompson, CEO and Founder of Kraig Biocraft Laboratories. “Her expertise and leadership have been essential in driving the development of our next-generation spider silk technology and in our adoption of new genetic engineering technologies. As we continue to push the boundaries of what’s possible in material science, Dr. Zhang’s vision and dedication will be instrumental in shaping the future of biomaterials.”

Throughout her career, Dr. Zhang has demonstrated a commitment to innovation in genetic engineering, making her a recognized leader in the field. Her work at Kraig Labs has accelerated the Company’s ability to create new advanced biomaterials.

“I am honored to take on this new role at Kraig Biocraft Laboratories,” said Dr. Zhang. “The advancements we’ve made in spider silk production are just the beginning of what’s possible. I look forward to continuing our groundbreaking work and bringing this incredible material to market at scale.”

Dr. Zhang’s appointment underscores the Company’s commitment to scientific excellence and innovation in biomaterials. As Kraig Labs advances its commercial rollout of spider silk-based textiles, her leadership will be critical in ensuring continued success in the field of bioengineered materials.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., April 1, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or the “Company”), a world leader in recombinant spider silk technology, today announced that it has secured four registered trademarks for its SpydaSilk^® brand. These trademarks represent a key milestone in the Company’s strategy to commercialize its revolutionary spider silk technology and position SpydaSilk^® as a premium apparel brand.

The newly secured trademarks provide legal protection for the SpydaSilk^® brand as Kraig Labs continues to expand its production capabilities and moves toward commercialization. SpydaSilk^® is a Singapore based joint venture company that Kraig Labs co-founded in 2021 to create a direct-to-consumer marketing channel for its spider silk materials. The Company is leveraging a blended strategy that includes both the independent development of the SpydaSilk^® brand and outreach to leading companies in key target markets, such as luxury fashion and high-performance apparel.

“The registration of these trademarks reinforces our commitment to building SpydaSilk^® into a globally recognized brand focused on quality and exceptional material performance,” said Kim Thompson, CEO and Founder of Kraig Labs. “With our spider silk production scaling up, we are positioning ourselves to introduce breakthrough products that merge sustainability with performance. We are actively engaging with industry leaders to explore collaborative opportunities that will bring our innovative materials to market.”

The Company’s proprietary recombinant spider silk fibers offer a combination of strength, elasticity, and softness, making them ideal for a range of high-value applications. Kraig Labs is engaging opportunities in luxury fashion and technical textiles to integrate its materials into next-generation products that redefine performance and sustainability standards.

With the recent expansion of its production operations, Kraig Labs remains focused on optimizing its recombinant spider silk output and finalizing product designs for commercialization. The Company anticipates that its dual-track approach—developing SpydaSilk^® as a standalone brand while also collaborating with industry leaders—will accelerate the adoption of its technology and drive revenue growth.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 24, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk biotechnology, today announced a groundbreaking scientific achievement in the development of high-performance biomaterials. Kraig Labs successfully engineered the largest known spider silk gene insert into silkworm—nearly doubling the previous record. This breakthrough represents a major step toward creating next-generation spider silk fibers with enhanced strength, flexibility, and performance potential.

The project was led by Dr. Xiaoli Zhang, the Company’s research manager, whose team continues to push the boundaries of genetic engineering for spider silk production.

“This milestone significantly expands the possibilities for spider silk technology,” said Dr. Zhang. “By increasing the size of the inserted spider silk genes, we are unlocking the potential for new materials with properties beyond what is currently achievable. This breakthrough lays the foundation for the future of high-performance silk fibers.”

While the sheer size of the genetic insert marks a scientific breakthrough, its real significance is not in its size but in the information this genetic packet carries. This allows for the creation of larger more complex proteins with unique mechanical properties for incorporation into the silk fibers. As Kraig Labs moves forward with this technology, the Company will explore the tremendous opportunities for increases in material performance these new larger packets allow.

This scientific accomplishment represents a bold step forward in material innovation and expands the possibilities of what can be achieved in material performance. Kraig Labs remains fully committed to the commercialization of its current recombinant spider silk production strains, even as it accelerates its development of more advanced materials. The Company is moving forward rapidly to advance the scale-up of its existing technologies, bringing spider silk fibers to market for applications in performance textiles, defense, and industrial sectors.

“Our mission is twofold: to commercialize our existing spider silk technology while continuously innovating for the future,” said Company CEO and founder, Kim Thompson. “This record-setting genetic achievement underscores the depth of our research capabilities and demonstrates our long-term vision for creating even more advanced biomaterials. Dr. Zhang and her team have taken a critical step toward making the next generation of spider silk a reality.”

Kraig Labs is currently accelerating its recombinant spider silk production, while also investing in the future of spider silk technology. The Company will continue to provide updates on both its commercialization efforts and its groundbreaking research.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 17, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs“), a world leader in spider silk manufacturing, is pleased to confirm it has established production operations in Lam Dong Province, Vietnam. This milestone marks the fulfillment of a long-standing strategic goal that the Company has pursued for more than a decade.

In January of this year, Kraig Labs announced the issuance of a new Investment Registration Certificate (IRC) for expanded production. This IRC was a critical regulatory achievement, paving the way for the Company to fully establish and scale its production in Vietnam’s premier silk-producing region.

As the heart of Vietnam’s silk production, Lam Dong Province is the ideal location for the Company’s expansion and investment into large-scale spider silk manufacturing. With the recently issued report by the Department of Finance in Lam Dong, Kraig Labs can now officially confirm its presence in the region.

With this key development, Kraig Labs is accelerating its production growth, positioning the Company to execute its ambitious expansion plans for 2025 and beyond. By establishing operations in Vietnam’s silk capital, the Company is strengthening its supply chain and scaling up its proprietary spider silk production.

“This is a transformative moment for Kraig Biocraft Laboratories,” said the Company’s Founder and CEO, Kim Thompson. “Establishing operations in Lam Dong has been a priority for more than ten years and now, with our footprint firmly in place, we are making significant investments to drive our production to unprecedented levels.”

As Kraig Labs continues to expand, the Company remains committed to leveraging its innovative technology to revolutionize the performance textiles industry while contributing to the development of Vietnam’s silk sector.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 10, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a global leader in engineered spider silk technologies, is thrilled to announce that it has begun production of the largest single batch of BAM-1 recombinant spider silk in the Company’s history. Last year, the Company publicly set a goal of exceeding all of 2024’s production with a single production batch in 2025. Today, Kraig Labs announces it has far exceeded that goal and kept that promise.

In 2024, Kraig Labs produced more spider silk than in all previous years combined. Following a record-breaking 2024, the Company is now surpassing that milestone with just a single production run in early 2025. This single production run is larger than the Company’s entire output for the previous 12 months. This extraordinary expansion underscores the Company’s continued success in scaling up the commercial production of its revolutionary spider silk technology.

“Today, we are making history,” said Jon Rice, Chief Operations Officer of Kraig Labs. “This production run is not just our largest to date—it is larger than everything we produced throughout all of 2024. This achievement demonstrates our ability to dramatically scale BAM-1 silk output, bringing us closer than ever to meeting what we see as an immense global demand for high-performance spider silk.”

The current BAM-1 silk production run is the latest in a series of breakthroughs that validate the Company’s robust spider silk production platform and its ability to deliver industrial-scale quantities of its cutting-edge biomaterial. Kraig Labs remains committed to pushing the boundaries of advanced material science, leveraging its scalable production systems to create unprecedented opportunities in technical textiles, defense, and performance apparel industries.

“As we continue to ramp up production, this milestone is a clear testament to the dedication of our team and the scalability of our technology,” said Rice. “We set out to revolutionize the performance materials market, and we are proving that spider silk is no longer a material of the future—it is here today and ready for commercialization.”

With this historic production milestone, Kraig Labs is further solidifying its position as the industry leader in spider silk manufacturing. The Company looks forward to sharing further updates as it advances toward commercial deliveries and strategic partnerships.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Paving the Way for Advanced Material Performance

ANN ARBOR, Mich., February 26, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), a leading developer of spider silk-based fibers, today announced a significant breakthrough in its genetic research program. The Company’s research team has successfully doubled the complexity and size of its spider silk gene insert package; a milestone expected to drive new advancements in material performance.

Building on its pioneering work in recombinant spider silk production, the Company’s latest achievement represents a major step forward in the development of next-generation fibers. By expanding the gene insert package, Kraig Labs aims to create more advanced silk materials with improved strength, elasticity, and durability—critical attributes for high-performance applications in technical textiles, defense, and medical industries.

“We believe that larger and more complex gene insert packages hold the potential to unlock superior material characteristics in our spider silk fibers,” said Kim Thompson, CEO and Founder of Kraig Labs. “This breakthrough reinforces our leadership in biomaterials innovation and sets the stage for the next evolution of spider silk technology.”

While this cutting-edge research progresses in the lab, Kraig Labs remains committed to bringing its revolutionary spider silk fibers to market. The Company’s production team continues its focus on commercial-scale spider silk manufacturing, with targeted material sales into multiple markets. Kraig Labs expects this will be a pivotal year for industry integration of spider silk.

“Our production team is on track to deliver commercial quantities of our spider silk this year, even as our research team pushes the boundaries of what’s possible in the lab,” added the Company’s COO, Jon Rice. “We are strategically balancing innovation and production to meet the growing demand for our game-changing materials.”

With its dual focus on both research and commercialization, Kraig Labs is solidifying its position as a global leader in spider silk technology. The Company remains dedicated to transforming the future of performance materials with bioengineered spider silk.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Successfully creates transgenic based on underwater adhesive properties of Caddisfly

ANN ARBOR, Mich., – February 10, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, proudly announces the successful creation of new novel silk, build upon the silk proteins of the remarkable caddisfly. This breakthrough marks a new frontier in the field of engineered fibers and underscores the Company’s commitment to pioneering innovations in biotechnology.

Caddisflies (known in the Pacific Northwest as “Periwinkles”) are known for their extraordinary ability to spin silk underwater, which they use to construct protective cases in aquatic environments. By leveraging the unique mechanical and chemical attributes of caddisfly silk proteins, Kraig Labs seeks to engineer materials with unprecedented functionality. This new silk offers the potential for increased durability when submerged in water. Possible applications for this new silk are vast, with exciting potentials for medical adhesives, biomedical textiles, performance apparel, and next-generation fiber technologies.

“This achievement demonstrates our ability to extend beyond spider silk proteins and explore the broader possibilities of silk engineering,” said CEO and Founder of Kraig Labs, Kim Thompson. “By tapping into the evolutionary diversity of silk-producing organisms, we’re expanding the toolkit for creating super fibers that meet the demands of tomorrow’s industries.” 

The introduction of caddisfly-based transgenic fiber represents a critical milestone in the Company’s vision to create new super materials blending the physical and chemical properties of various silk proteins. The result is an ever-growing portfolio of high-performance materials designed to redefine the standards of strength, elasticity, and functionality.  These new fibers will leverage the Company’s propriety silkworm-based production system to bring these materials to market.

“Incorporating the unique and incredible adhesive properties of caddisfly silk protein has been a key part of the R&D roadmap I laid out when founding Kraig Labs,” Thompson continued. “Unveiling this pivotal scientific milestone, our first caddisfly-based transgenic, marks not only a significant leap forward for the Company’s business model but also a deeply gratifying achievement for me personally and for our team.”

This breakthrough would not have been possible without the dedication and ingenuity of the Company’s scientific team. Their relentless pursuit of excellence and creative problem-solving have once again positioned Kraig Labs at the forefront of biotechnological innovation.

“Our team’s success with this caddisfly-inspired material is a testament to the power of combining cutting-edge science with bold vision,” added the Company’s COO, Jon Rice. “We are excited about the potential this fiber holds and the new opportunities it creates across multiple sectors.”

Kraig Labs is committed to pushing the boundaries of creativity and science in silk protein engineering. The Company has filed a provisional utility patent application for this exciting new technology. By exploring and integrating the diverse properties of silk from various species, the Company will continue to lead the charge in developing sustainable, high-performance materials that address real-world challenges.

For details about other recent advancements that Kraig Labs has made, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 23, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), a leading developer of spider silk-based fibers, proudly announces that it has received a new investment license in Vietnam. This strategic authorization marks a significant milestone in the Company’s mission to expand its production operations to meet the growing demand for its high-performance spider silk materials.

The newly acquired investment license empowers Kraig Labs to scale its production operations significantly and begin addressing the growing requests for materials and requests for quote that it has been fielding. This expansion will bolster the Company’s ability to provide its innovative materials to a broad spectrum of markets, including textiles, defense, and medical sectors, eagerly anticipating these breakthrough fibers’ commercial availability.

“We are thrilled to secure this new investment license in Vietnam. This license is a testament to our commitment to expanding our production capabilities and the confidence the team placed in our technology,” said Founder and CEO of Kraig Labs, Kim Thompson. “This license positions us to grow our production footprint and fulfill the increasing demand for materials. This expansion is moving us forward with our vision for cost-effective spider silk production become a reality.”

The Company’s expansion plans in Vietnam include developing advanced rearing facilities and increasing the production of its advanced materials. The Company remains committed to environmentally sustainable practices, leveraging its biotech innovations to deliver materials that are strong, lightweight, and eco-friendly.

This development aligns with Kraig Labs’ vision to revolutionize material science by bringing to market one of the most sought-after and impactful biomaterials of the 21st century.

For details about other recent advancements the Company has made, please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com